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Cryptococcal meningitis is a life-threatening opportunistic fungal infection in both HIV-infected and HIV-uninfected patients.
According to the most recent taxonomy, the responsible fungus is classified into a complex that contains two species (Cryptococcus
neoformans and C. gattii), with eight major molecular types. HIV infection is recognized worldwide as the main underlying disease
responsible for the development of cryptococcal meningitis (accounting for 80–90% of cases). In several areas of sub-Saharan
Africa with the highest HIV prevalence despite the recent expansion of antiretroviral (ARV) therapy programme, cryptococcal
meningitis is the leading cause of community-acquiredmeningitis with a highmortality burden. Although cryptococcal meningitis
should be considered a neglected disease, a large body of knowledge has been developed by several studies performed in recent
years.This paper will focus especially on new clinical aspects such as immune reconstitution inflammatory syndrome, advances on
management, and strategies for the prevention of clinical disease.
1. Introduction
The encapsulated yeast, Cryptococcus spp., is a major cause
of fungal meningitis and meningoencephalitis especially in
immunocompromised patients [1, 2]. This basidiomycete
fungus was first isolated in 1894 by Sanfelice in fruit juices
and subsequently recovered from the tibial lesion of a patient
by Busse and Buschke [3–5].The genus has been named from
the Greek words, kryptos (hidden) and kokkos (berry) but a
long lists of names and synonyms have been generated until
the adoption of the actual nomenclature [6].
However, although C. neoformans has been recognized
for more than 100 years, the worldwide spread of HIV
infection as well as the increasing number of patients with
impaired immunity were responsible for the dramatic surge
of this life-threatening infection only in the 80’s [7–9].
Although effective treatment for HIV disease has decreased
significantly incidence of cryptococcal meningitis (CM) in
western countries, it remains a common cause of infec-
tiousmorbidity andmortality especially amongHIV-positive
patients living in sub-Saharan Africa and South-east Asia
[10–16]. This paper will focus on main aspects of AIDS-
associated cryptococcal meningitis with special attention
on recent findings on immune reconstitution inflammatory
syndrome, diagnosis, treatment, and prevention. Data were
identified by searches on PubMed and Scopus using a com-
bination of search terms including “cryptococcosis,” “AIDS,”
“immune reconstitution inflammatory syndrome,” “cryp-
tococcal antigen,” “cryptococcal meningitis,” “cryptococcal
diagnosis,” “antifungal treatment,” “primary prophylaxis,”
and “prophylaxis discontinuation.”Moreover references from
relevant key articles and frommyownfileswere included.The
final search date was October 2012.
2. Biology, Microbiology, and
Serotypes Distribution
More than 30 species of the genus Cryptococcus exist but
only two are considered important human pathogens. The
fungus is actually classified into the Cryptococcus neoformans
complex that consists of two species: C. neoformans and
C. gattii [17–19]. C. neoformans var. grubii (serotype A), C.
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Figure 1: Worldwide geographic diffusion of different serotypes of Cryptococcus neoformans complex (based on [25–48]).
neoformans var. neoformans (serotype D), and AD hybrids
generally cause disease in immunocompromised patients
whereas C.gatti (serotype B and C) can cause disease also in
immunocompetent patients [9, 20–22].
Molecular typing has identified eight major molecular
types within the 2 species: VNI/AFLP1, VNII/AFLP1A (C.
neoformans var. grubii), VNIII/AFLP3 (AD hybrid), VNIV/
AFLP2 (C. neoformans var. neoformans), and VGI/AFLP4,
VGII/AFLP6, VGIII/AFLP5, VGIV/AFLP7 (C. gattii) [23].
Non-neoformans cryptococcal infections are rarely
encountered and have been recently reviewed [24].
C. neoformans var. grubii has a worldwide distribution
and is the most prevalent species (Figure 1) whereas C. neo-
formans var. neoformans is found predominantly in Western
Europe [25–37]. Cryptococcus gattii was originally known
to be geographically restricted to tropical and subtropical
regions [38–40] but, since 1999, an unprecedented emergence
ofC. gattiiwas observed in the east coast of Vancouver Island,
British Columbia where the organism is now endemic and
where the incidence is the highest ever reported (37 times
greater than reported in Australia) [41, 42]. Moreover, there
is recent evidence that the C. gattii strain of the Vancouver
outbreak has spread to the Pacific Northwest of the United
States [43]. Finally, in recent years C. gattii has been isolated
also in temperate regions of Europe (Austria, Italy, Spain,The
Netherlands) as well as of Asia (Japan, South Korea) [44–47].
3. Epidemiology and Risk Factors
The analysis of the risk factors associated with develop-
ment of cryptococcosis employed in several studies clearly
demonstrates that HIV infection is the major underlying
condition predisposing to the development of this disease
[8, 33, 48]. Several studies have underscored the profound
impact that the emergence ofHIV/AIDS epidemic has had on
the epidemiology of cryptococcal infection [8, 12, 13, 49, 50];
in fact, it has been reported that there were 1264 proven
cases of cryptococcosis in the United States during the 12-
year period from 1965 to 1977 [51]. In contrast a 1500%
increase was observed in the period from 1981 to 1990 due
to the AIDS epidemic; because of the introduction of azoles
therapy and, by themid-90s, of the highly active antiretroviral
therapy (HAART), a declining incidence was observed in
all Western countries [10–13, 52]. A completely different
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situation is registered in sub-Saharan Africa: worth noting
an increasing numbers of cases of CM were observed among
youngCongolese adults starting from the early 60s possibly as
the beginning of theHIV epidemic [53]. In a large part of sub-
SaharanAfrica as demonstrated by a recent controlled clinical
trial conducted on bacterial meningitis, as well as in other
studies,C. neoformans is now emerged as the leading cause of
meningitis accounting for 26 to 45% of cases in several series
[54–57].
It has been estimated that in 2006 at least 957,900 cases of
CM had occurred worldwide with the highest burden from
sub-Saharan Africa (720,000 cases with 504,000 deaths) [1]
Moreover, despite the fact that also in sub-Saharan Africa, an
increasing number ofHIV-positive patients are now receiving
HAART, a study conducted in South Africa which showed
that the number of new India ink positive cases of CMwas not
falling [58]. However, in Burkina Faso where the incidence
of HIV infection was lower and probably where better ART
programs are employed, a steady decline of CMwas observed
during an 8-year period in parallel with the increased use of
HAART [59]. Both studies are a reminder of the importance
of more huge implementation of ART in Africa with a more
widespread and earlier access to these life-saving therapies.
4. Pathogenesis
The portal of entry of Cryptococcus is usually through inhala-
tion of spores or desiccated yeast cells from the environment.
Deposition in the alveoli produces an asymptomatic infection
that is either cleared or controlled by a strong cell-mediated
immune response leading to a dormant latent infection with
development of granuloma in the lungs or hilar lymph nodes
[60, 61]. In immunocompromised individuals, the fungus
can spread from the lungs to the central nervous system to
cause meningoencephalitis that is fatal if left untreated.Once
C. neoformans enters the circulatory system it must survive
for dissemination to occur and macrophage can be a vehicle
either for dissemination and distribution through the host;
crossing the blood brain barrier (BBB) is probably medi-
ated by transcytosis (i.e., transcellular penetration through
microvascular endothelial cells) and there is evidence that the
capsule is involved [62, 63].
Macrophages probably play also an important role in the
BBB crossing by C. neoformans with a mechanism of “Trojan
horse”; it has been shown in vitro that active macrophage
phagosomal extrusion is a possible escape strategy allowing
continued propagation and dissemination of the fungus [64].
Recently, Charlier et al. presented proofs of concept for the
hypothesis of the Trojan horse in a mouse model comparing
intravenous inoculation of the yeast in a free form and after
ingestion by cultured monocytes [65].
5. Clinical Manifestations
The fungus Cryptococcus can infect any organ in the body
but showing a predilection for the lung and the central
nervous system (CNS). The lung is the usual portal of entry
of the microorganism and the infection can run either an
asymptomatic course, especially among immunocompetent
subjects, or progress to a life-threatening pneumonia with
respiratory failure as observed in patients with AIDS [66].
In the pre-HAART era, cryptococcal infection was iden-
tified as the only cause of acute respiratory failure in 9%
of a cohort of 210 patients with AIDS [66]; black race, lac-
tate dehydrogenase, lactate dehydrogenase level >500 IU/L,
presence of skin lesions, and interstitial infiltrates were
the variables independently predictive of developing acute
respiratory failure [66]. In a case series of 18 HIV-positive
patients diagnosed with cryptococcal meningitis, Driver et
al. found that 78% had respiratory symptoms during the 4-
month period before meningitis appeared as compared with
50% at the time of diagnosis [67]. More recently,in Uganda
among HIV-infected subjects hospitalized with pneumonia
and undergoing bronchoscopy, the diagnosis of pulmonary
cryptococcosis was made in 11% of cases [68]. Worth noting
the diagnosis of pulmonary cryptococcosis was unsuspected
in all these cases before diagnostic testing, thus confirming a
lack of awareness of this pulmonary pathogen, as described
in an autopsy study conducted on south African miners
[69]. Among HIV-infected hospitalized patients with acute
respiratory infections in ruralThailand, Cryptococcus species
was found to be the second leading infection (after tubercu-
losis), and in 43% of all cryptococcal antigen positive, there
was no evidence of past or concomitant meningitis nor any
alternative etiology was identified [70].
C. neoformans shows a predilection to invade the central
nervous system causing meningitis or meningoencephalitis
in about 77–86% of patients [2, 71–89]; usually CM presents
itself with a subacute or chronic course but occasionally may
be fulminant [71]. Signs and symptoms of presentation may
vary according to the host with fever and headache more
frequently observed in the HIV-positive subjects (Table 1)
and altered mental status among HIV-negative people [2, 7,
20, 27, 28, 55–57, 72–90]. In the HIV-positive patient CM
is a late opportunistic infection usually observed when the
T lymphocyte CD4+ cell count falls below 50–100/𝜇L; two-
thirds of patients had less than 50 CD4+ cells/𝜇L and the
median value reported in several series is below 30/𝜇L [2, 77,
79].
Meningismus or neck stiffness is observed globally in
about 61% of cases but more frequently in HIV-positive
patients in Africa [28, 55–57, 80–85] compared to HIV-
positive patients in Western countries [7, 20, 71–77] or HIV-
uninfected patients [2, 20, 27, 79, 87, 89, 91]. However, this
finding may reflect a delayed presentation in sub-Saharan
Africa in comparison with patients observed in western
countries. Alteredmental status, which is themost important
predictor of poor outcome of patients with CM, is present in
18–28% of patients with AIDS and in half of those without
HIV infection (Table 1) [72–90]. Fungemia, expression of
disseminated disease is observed in 47–71% of HIV-positive
patients but only in 27% of HIV-negative subjects affected
by cryptococcosis. Ocular involvement with visual changes is
reported in near one-third of HIV-infected patients. Several
manifestations can occur such as oculomotor palsies, retinal
hemorrhages, and endophthalmitis [91–94]. Vision loss may
be due to yeasts infiltration of optic nerve or may be caused
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Table 1: Clinical and mycological features of cryptococcal meningitis.
Signs and symptoms
HIV-positive
patients,
𝑛 = 1366
∗
HIV-positive
patients, Africa,
𝑛 = 4149
†
HIV-negative
patients,
𝑛 = 675
#
Total,
𝑛 = 6190
HIV-positive
children,
𝑛 = 160
∧
Headache 839/1014 (82.7) 2646/3324 (79.6) 292/500 (58.4) 3777/4838 (78.1) 40/60 (66.7)
Fever 812/1080 (75.2) 1914/3322 (57.6) 352/500 (70.4) 3078/4902 (62.8) 31/60 (51.7)
Cough 267/994 (26.9) 16/67 (23.9) 78/324 (24.1) 361/1385 (26.1) NR
Dyspnea 119/872 (13.6) NR 56/292 (19.2) 175/1164 (15.1) 7/47 (14.9)
Meningismus or neck stiffness 342/889 (38.5) 2240/3330 (67.3) 181/453 (39.9) 2763/4672 (59.1) 14/56 (25)
Visual changes 171/593 (28.8) NR 2/16 (12.5) 173/609 (28.4) 1/40 (2.5)
Altered mental status 203/1080 (18.8) 937/3347 (27.9) 236/451 (52.3) 1378/4878 (28.2) 15/60 (25)
Seizures 28/456 (6.1) 304/3323 (9.1) 48/458 (10.5) 380/4237 (8.9) 9/60 (15)
Skin lesions 19/321 (5.9) NR 6/32 (18.7) 25/343 (7.3) 1/60 (1.6)
AIDS-defining illness 540/1101 (49) 484/568 (85.2) — 1024/1669 (61.3) 8/30 (27)
Mycology
Positive CSF culture 1200/1274 (94.2) 3030/3364 (90.1) 381/464 (82.1) 4611/5102 (90.4) 97/110 (88.2)
Positive CSF antigen 489/530 (92.3) 1693/1757 (96.3) 432/447 (96.6) 2614/2734 (95.6) 38/62 (61.3)
Positive India ink 886/1132 (78.3) 3075/3360 (91.5) 269/456 (58.9) 4230/4948 (85.5) 44/50 (88)
Positive serum antigen 292/305 (95.7) NR 121/141 (85. 8) 413/446 (92.6) 10/34 (29.4)
Positive blood cultures 645/1369 (47.1) 371/524 (70.8) 106/395 (26.8) 1122/3991 (28.1) 22/43 (51.2)
NR: not reported.
∗References [7, 20, 72–80].
†References [28, 55–57, 81–86].
#References [20, 79–81, 87–91].
∧References [100–103, 105].
by increased intracranial pressure [95]. Permanent blindness
was associated with visual loss within the first week of
hospital admission [94].
Skin lesions due to C. neoformans are found in 6%
of AIDS patients with CM but the frequency is higher
in patients infected with serotype D due to the seemingly
higher skin tropism of this serotype [96–98]. Skin lesions are
usually expression of the haematogenous dissemination of
the fungus and can be single or multiple and present with a
wide variety of pictures (papules, pustules, vesicles, nodules,
ulcers) although a molluscum contagiosum-like appearance
is the most frequently reported (Figure 2).
6. Cryptococcosis in Children
Cryptococcal disease seems to occur less frequently in AIDS
children than in adults with a prevalence of 0.8 to 1.4%
[99–101]. However, in Thailand a 2.97% point prevalence
was observed during an eight-year study among hospitalized
HIV-infected patients [102]. In South Africa, in the largest
study so far conducted, the incidence of cryptococcosis
among HIV-positive children was 47 cases per 100.000
persons [103].Median age at time of diagnosis was 7 years that
is similar to the figures (7.8 and 9.8 years) previously reported
in the literature [103–105]. In the South Africa experience,
there was the demonstration of the highest incidence among
childrenwith less than 1 year of agewith a second peak among
children in the 5-through 10-year age group [103].
Older studies suggested that children with HIV infection
acquired by vertical transmission may be less likely to
develop C. neoformans infection than children infected by
other routes [100, 117]. However, these observations were not
confirmed in those studies conducted in Africa and may
reflect the fact that the predominant risk for pediatric AIDS
at the beginning of epidemic was transfusion [101, 102].
Clinical features in children were similar to those
observed in adults but those diagnosed in Africa showed
higher frequency of headache (86% versus 53%), nuchal
rigidity (69% versus 7%), seizures (38% versus 13%), and
focal neurologic signs (23% versus 7%) in comparison with
patients observed in USA [100, 101].
7. Elevated Intracranial Pressure
Elevated intracranial pressure (ICP) is a common complica-
tion ofAIDS-associatedCM.Thepathophysiology of elevated
ICP in patients with CM is poorly understood and it is likely
caused by several convergent factors. It has been postulated
that it may be due to the outflow obstruction precipitated
by aggregation of fungal polysaccharide accumulating in
arachnoid villi and subarachnoid spaces thus providing the
blockage of the channels for CSF drainage [118]. This picture
is consistent with communicating hydrocephalus. More-
over, another possible important factor is cerebral oedema
resulting from cytokine-induced inflammation and possibly
osmotic effect by fungus-derived mannitol [119].
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Figure 2: Patients with cryptococcal meningitis and disseminated
infection with multiple papular and molluscum-like lesions on the
face.
In an old observational study about 60% of the patients
had an intracranial pressure of ≥250mmH
2
O, 30% of whom
showed an intracranial pressure of ≥350mm H
2
O [119].
Similar results were subsequently confirmed in two large
studies showing that 19–27% of patients with CM have a CSF
pressure of ≥350mm H
2
O [120, 121]. The highest value of
CSF opening pressure is consistently associated with higher
fungal burden, significantly more frequent observation of
papilledema, hearing loss, meningismus and increased risk of
early mortality [119, 120]. However this latter finding was not
confirmed in the study of Bicanic and coworkers [121].
A recent autopsy study elegantly demonstrated a correla-
tion between high concentration of viable and dead organ-
isms in the arachnoid granulations and raised cerebrospinal
fluid pressure with the consequence of the obstruction of CSF
resorption [122].
The optimal management of elevated ICP without hydro-
cephalus in the setting of CM is still uncertain and debated.
The updated guidelines by the Infectious Diseases Society of
America on the basis of the study by Graybill and coworkers
recommend, after appropriate brain imaging to exclude
hydrocephalus or space-occupying lesions, CSF drainage by
lumbar puncture (with a BII evidence) [123]; if symptoms
persist with concomitant high CSF pressure (>250mmH
2
O)
daily drainage by repeated lumbar puncture or positioning
of temporary percutaneous lumbar drains is recommended
(with a BIII evidence). However, daily lumbar punctures
although associated with immediate relief of headache may
be associated with the risk of brain herniation [124].
The placement of lumbar drains has been proposed for
control of raised ICP when the more conservative measures
have failed; this technique allows the removal of more
cerebrospinal fluid than can be safely removed by daily
lumbar puncture [125, 126]. The use of temporary lumbar
drainage has been used also in resource-poor setting without
significant increase of bacterial infections [127]. Finally, the
use of permanent ventriculoperitoneal shunts can be reserved
for patients with true hydrocephalus or raised ICP refractory
to all other measures employed [128].
8. Cryptococcal Immune Reconstitution
Inflammatory Syndrome (IRIS)
Cryptococcal immune reconstitution inflammatory syn-
drome (IRIS) can be associated with a clinical deterioration
of the disease or with a new presentation of cryptococcal
disease after reversal of the immune deficiency state [129,
130]. Cryptococcal IRIS has been initially described in HIV-
infected patients after starting highly active antiretroviral
therapy (HAART) but it has been subsequently recognized
also in the transplantation setting and following treatment
with adalimumab and alemntuzumab [131–133]. Recently a
group of experts on behalf of the International Network
for the Study of HIV-associated IRIS (INSHI) proposed the
adoption of two clinical case definitions of IRIS associ-
ated with cryptococcosis among HIV-infected patients: (1)
paradoxical cryptococcal IRIS involving patients who had
a diagnosis of cryptococcal disease before starting ART;
(2) ART-associated cryptococcosis characterized by incident
or unmasking cryptococcosis after starting antiretroviral
treatment [134].
The incidence of paradoxical IRIS associated with crypto-
coccosis in AIDS patients was reported to be 15.9 events/100
patient-years of follow-up (95% CI 8.5–22.9) in one study
from USA, 4.2/100 person-years(PY) of follow-up (95% CI
2.2–7.8) in another study conducted in France, and 25/100 PY
in South Africa [135–137].
On the other hand, the incidence of unmasking (or
ART-associated) IRIS is lower ranging from 0.2% to 1.6% as
reported in two retrospective and three prospective studies
[110, 137–140].
A meta-analysis of 54 cohort studies comprising more
than 13.000 patients starting HAART indicated that CM
was associated with the development of IRIS in 19.5% of
cases (95% CrI 6.7–44.8%). It ranked second among the
opportunistic infectionsmore frequently associatedwith IRIS
but, more notably, had the highest mortality attributed to
the syndrome (20.8%) [141]. However, the study by Muller et
al. was criticized because it failed to distinguish paradoxical
from unmasking IRIS with the possible underestimate of the
true frequency of paradoxical-cryptococcal IRIS [142]. The
differences in the incidence of cryptococcal IRIS reported
across different studies probably reflect the typology of the
study (retrospective versus prospective), different clinical
definitions employed, and different settings (resource-limited
countries versus high-income countries). However, what
is undoubted is the fact that cryptococcal IRIS is a true
problem with an high expected burden especially in sub-
Saharan Africa, Southeast Asia and Latin America [143].
The pathogenesis of cryptococcal IRIS is complex and not
fully understood but is mainly attributable to the severe
immunodeficiency that is unable to clear the foreign antigens
and the subsequent cytokine storm induced by the restored
inflammatory response [144].
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Another controversial point is the establishment of the
period of time during which the patients are at risk of
developing cryptococcal IRIS. In fact, the time of appearance
of IRIS varied quite widely among the different studies with
the shortest interval after the start of HAART reported to be
few days and the longest 22–27 months [145–148]. However,
in four studies (two retrospective and two prospective)
performed on patients affected by cryptococcosis the median
time elapsing between initiation of HAART and onset of
IRIS was reported to be 30 days (range 3–330 days) [135],
44 days (range 36–62 days) [149], 63 days (range 12–129
days) [150], and 8 months (range 2–37 months) [136]. It is
plausible that the observed discrepancy can be explained
by differences in the clinical pictures presented with less
central nervous system involvement in the study reporting
the longest interval [135]. This finding is in keeping with
the results of a review of 25 episodes of IRIS-associated
cryptococcosis showing amedian time interval of 3.5 months
for patients with CNS manifestations compared to 7 months
for those with lymphadenitis [151].
In the case definition elaborated by the experts of INSHI,
they proposed a maximum time of 12 months for the devel-
opment of paradoxical IRIS after ART initiation; although
acknowledging that the cut-off chosen was largely arbitrary
and would exclude those occasional cases presenting after
a longer interval, they believed that it might improve the
specificity and its practical usefulness [134].
In a retrospective multicentre study from France, a diag-
nosis of cryptococcosis revealing HIV-infection (OR 4.8),
presence of fungemia at baseline (OR 6.1), CD4 cell count of
less than 7/𝜇L (OR 4.0) and startingHAARTwithin 2months
of diagnosis of cryptococcosis (OR 5.5) were identified in a
multivariate model as independent risk factors for develop-
ment of IRIS [136]. Another retrospective cohort study from
USA showed that patients who had started HAART within
30 days after the diagnosis of cryptococcosis were more likely
to develop IRIS (RR 1.73, 95% CI 1.03–2.29; 𝑃 = .031) [135].
On the contrary, Bicanic et al. in a prospective observational
study conducted in South Africa on 65 antiretroviral naı¨ve
patients affected by CM were unable to find any association
with fungal burden, baseline CD4 cell count, HIV viral load
and time to start ofHAART, and the subsequent development
of IRIS [149]. They showed that a more rapid and strong
immunological response measured at 6 months (220 versus
124 CD4 cells/𝜇L, 𝑃 = 0.01) was the only variable associated
with development of IRIS [149]. Finally, in Thailand the
investigators found a higher baseline cryptococcal antigen as
the only risk factor associatedwith development of IRIS [150].
Interestingly in a prospective study conducted in a
cohort of ART-na¨ıve Ugandans that aimed to identify serum
biomarkers predictive of IRIS development, a 4-fold higher
baseline concentrations of cryptococcal antigenwas observed
among patients who developed IRIS in comparison with
those who did not develop IRIS [152]. In the same study
higher levels of IL-4 and IL-17 and lower levels of TNF-𝛼,
granulocyte colony-stimulating factor (G-CSF), granulocyte-
macrophage colony-stimulating factor (GM-CSF), and vas-
cular endothelial growth factor (VEGF) were predictive of
IRIS with a receiver operating characteristic (ROC) curve of
Figure 3: India ink preparation of cerebrospinal fluid showing yeast
cells some of which budding surrounded by large capsule (Courtesy
Dr Giuseppe Giuliani).
0.82. The same group showed that a paucity of inflammation
in the cerebrospinal fluid at the time of CM is associated
with failure to sterilize CSF at 2 weeks and subsequent risk
of developing IRIS [153].
Clinical presentation of paradoxical IRIS can range from
the more frequent picture of relapsing meningitis with raised
intracranial pressure and negative CSF culture [13, 130, 135,
136, 138–140, 145, 149, 150, 154–158] to other less frequent
central nervous systemdiseases (i.e., cerebral cryptococcoma,
intramedullary abscess, cerebellitis with mass effect, visual
and hearing loss, and radiculitis) [135, 136, 146, 147, 159–
163] or alternatively may present with extraneural pictures
(Table 3). Lymphadenopathy [128, 135, 136, 145, 147, 151, 158,
164], pulmonary disease, including cavitating,necrotizing
and nodular lesions [130, 136, 165], subcutaneous abscess
and erosive bone lesions [129, 164, 165] are the extraneural
manifestations of paradoxical cryptococcal IRIS. The clinical
manifestations of ART-associated cryptococcosis (compris-
ing also unmasking disease) are essentially similar, with
a predominance of meningitis [110, 129, 135, 149], lym-
phadenopathy, and subcutaneous abscesses [166–170].
Cryptococcal IRIS, especially when presenting with CNS
manifestation, is a potentially lethal disease [136, 140, 145,
149, 151, 157] with an average fatality of about 20% [141].
Different approaches in themanagement of this complication
have been employed including anti-inflammatory steroidal
[136, 145, 155, 156, 160, 164], and nonsteroidal therapy [164,
165], thalidomide [136], anti-TNFmonoclonal antibody [171],
surgery [130, 136, 147, 151], and antifungal therapy (including
increased dosage, change of drug or resumed antifungal
therapy) [129, 130, 151, 154, 155, 157, 159].
9. Laboratory Diagnosis
A definitive diagnosis of CM is made by positive CSF culture
and/or direct identification of the organism bymeans of India
ink staining (Figure 3). Cryptococcus neoformans, however, is
able to disseminate and infect most areas of the body (i.e.,
lung, skin, lymph node, spleen, liver, prostate, eye, bone, bone
marrow, heart, thyroid, adrenal gland,muscle) and thus it can
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Figure 4: Liver histology showing PAS-positive yeast cells in a case
of disseminated cryptococcosis (Courtesy Dr. Carlo Parravicini).
be cultured or shown by histopathology as well from different
body specimens (Figure 4). Blood cultures are reported to be
positive in 47–70% of HIV-infected patients as compared to
21% of HIV-uninfected patients with CM (Table 1).
A presumptive diagnosis of CM can be made on the
basis of a positive cryptococcal antigen (CrAg) using a latex
agglutination or an enzyme immunoassay kit. Cryptococcal
antigen testing on blood andCSF is a highly reliable and rapid
diagnostic technique with excellent sensitivity and specificity
[172]. Sensitivity of CSF cryptococcal antigen test is 92%
to 96% in patients with culture-proven CM (Table 1). False
positive results are associated with rarer infections due to
Trichosporon beigelii, Capnocytophaga canimorsus, and Stom-
atococcus mucilaginosus and, on the contrary, false negative
results are observed either with poorly encapsulated organ-
isms and low fungal burden or the prozone phenomenon
[173–175].
HIV-positive patients usually have very high serum and
CSF CrAg titres than their HIV-negative counterpart as
a reflection of the higher yeast burden and, in the pre-
HAART era, both were predictive of mycological failure and
poor outcome [8, 13]. In one cohort study conducted in
Uganda among HIV-infected adults, detectable cryptococcal
antigenemia preceded symptoms by a median of 22 days and
approximately 11% of people had cryptococcal antigenaemia
for more than 100 days [28].
In areas of high prevalence of cryptococcosis, the use of
serum CrAg as a screening test is helpful to identify those
HIV-infected people with advanced disease at risk of devel-
oping cryptococcal meningitis and who might benefit of a
preemptive antifungal treatment together with antiretroviral
therapy [107–110, 113]. A summary of studies reporting on
detection of CrAg is reported in Table 2 [28, 106–116].
Using a cut-off value of >1 : 8 the CrAg assay was 100%
sensitive and 96% specific for predicting incident CM during
the first year of HAART [109]. Subsequently, in a prospec-
tive observational study conducted in Kampala (Uganda),
Meya and coworkers showed that CrAg testing targeting
people with severe immunodeficiency (less than 100 CD4+
cell/𝜇L) was a cost-effective measure showing 71% survival
at 30-month of those treated with fluconazole together with
HAART compared with 100% deaths within 2 months in
those treated only with HAART [110].
In 2009, a new lateral flow assay (LFA) characterized
by rapidity (5–15 minutes), stability at room temperature,
and affordability (1.5 to 2.5 US $) was developed for the
detection of cryptococcal antigen on serum, CSF, and urine
[198]. All the above mentioned characteristics made it an
ideal test to be used at point-of-care (POC) in resource-
limited countries. This dipstick assay has been evaluated and
validated against EIA positive sera and Cryptococcus positive
blood culture from HIV-positive patients from Thailand,
showing sensitive ranging from 96% to 100%, respectively
[199]. In another retrospective study using serum, plasma
and urine from patients with HIV-associated cryptococcal
meningitis sensitivity was 100% for serum and plasma and
98% for urine [200]. It has been suggested that the ratio of
titres measured by latex agglutination (LA) in comparison
with LFA is 1 : 5 [201] but a small study found imperfect
agreement (LFA:LA 1.53 with confidence limits from 0.13 to
18.1) [202]. Based on all the above mentioned studies, it has
been proposed to integrate CrAg as a screening test into
routine HIV care not only in resource-limited settings but
also in western countries [200, 202, 203].
Finally two studies showed cross-reactivity between the
Platelia Aspergillus galactomannan assay and serum from
patients with cryptococcal meningitis with positive results
ranging from 13.6 to 63.3% [204, 205].
10. Prognosis and Outcome
Left untreated CM is a uniformly fatal disease but even with
antifungal treatment the outcome is influenced either by
factors associated with the host and the underlying diseases
and the fungus [206]. Several studies have confirmed that
abnormal mental status [14, 74, 207], high cerebrospinal
fungal burden (demonstrated by high cryptococcal antigen
titers or colony forming unit) [20, 74, 76, 77, 122, 183,
184, 207], disseminated infection [20], wasting syndrome
(low body mass index) [83] symptomatic elevated ICP [121],
low CSF leukocyte cell counts [14, 71], lack of flucytosine
treatment during induction phase [20], induction treatment
with low dose fluconazole [82, 85, 207] are factors associated
with poor outcome of AIDS-related CM.
In the AntiretroviralTherapy Cohort Collaboration study
(including 15 cohorts with over 31,000 HIV-positive patients
without prior AIDS-defining events who started HAART),
cryptococcosis ranked third (after non-Hodgkin lymphoma
and progressive multifocal leukoencephalopathy), as a cause
of death overall and within the first 6 months after the
beginning of therapy [208]. However, the introduction of
HAART has witnessed a marked increase of survival of
patients with cryptococcal meningitis either in resource
poor- and in high-income countries [13, 14, 209]. The 14-day
survival rates among antiretroviral-naı¨ve persons with CM
was 49% in 2001-02 and 80% in 2006 in Kampala, Uganda
[14]. However, the 1-year survival rate in Uganda remains 4-
fold worse than in France and 2-fold worse than in Thailand
even with the availability of HAART [20, 210]. Another
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Table 2: Summary of published studies regarding cryptococcal antigenaemia in HIV-positive patients.
Author, year of
publication, reference Country
Type of
study/Population
CrAg asymptomatic
prevalence
All CrAg
positive Comment
Africa
Desmet et al., 1998 [106] Kinshasa,Zaire Cohort/450 adults 15/450 (3.3%) 55/450 (12.2%)
29 out of 44 had CSF positive
microscopy/culture for C.
neoformans
French et al., 2002 [28] Entebbe,Uganda Cohort/1372 adults 7/77 (9.1%) 77/1372 (6.6%)
CrAg preceded onset of
symptoms by a median of 22
days
Tassie et al., 2003 [107] Mbarara,Uganda Cohort/197 adults 8/197 (4.1%) 21/197 (10.7%) 13 pts had CM
Liechty et al., 2007 [108] Kampala,Uganda
Retrospective/395
adults 22/377 (5.8) 44/395 (11.1)
7 pts newly diagnosed with
CM, 3 of whom had a
positive serum CrAg at
baseline; asymptomatic
CrAg independent risk
factor for death (RR 6.6)
Jarvis et al., 2009 [109] Cape Town,South Africa
Retrospective/707
adults 25/707 (3.5)
∗ 46/707 (7%)
13 out of 46 (28%) developed
new or relapsed CM; CrAg
independent risk factor for
death (HR 3.1)
Meya et al., 2010 [110] Kampala,Uganda
Prospective cohort/609
adults
33/592 (5.6%)
26/295 (8.8% incidence)
< 100 CD4+/𝜇L
7/298 (2.3%)
> 100 CD4+/𝜇L
50/609 (8.2%)
17 had pre-Art diagnosed
CM; preemptive treatment
cost-effective (NNTac 6.5;
NNTad 10)
Mamoojee et al., 2011
[111]
Kumasi,
Ghana Retrospective/92 adults 2/92 (2%) 2/92 (2%)
This study suggested a
limited value of CrAg testing
in this area
Oyella et al., 2012 [112] Kampala,Uganda
Cross-sectional/367
adults 45/367 (12.2%) 69/367 (18.8%)
Only 30 pts undergo lumbar
puncture; 24 out of 30 had
CM
South-east Asia
Micol et al., 2007 [113] Phnom Penh,Cambodia
Prospective cohort/327
adults 10/327 (3.1%) 58/327 (17.7 %) 41 pts had CM
Pongsai et al., 2010 [114] Bangkok,Thailand
Retrospective/131
adults 8/131 (6.1%) 12/131 (9.2%)
3 out of 12 had CM, 1
pulmonary cryptococcosis
Europe and USA
Feldmesser et al., 1996
[115] USA Case series/10 adults 7/10 (70%) 10
First study about isolated
CrAg
Patel et al., 2013 [116] London, UK Retrospective/157adults 1/157 (0.6%) 7/157 (4.4%) 7 pts diagnosed with CM
CrAg: cryptococcal antigenemia, CM: cryptococcal meningitis, UK: United Kingdom; RR: relative risk; HR: hazard ratio; NNTac: number needed to treat to
avoid a case; NNTad: number needed to treat to avoid death.
∗Only patients without a history of cryptococcal meningitis were considered.
important point is the still high early mortality associated
with CM that is apparently not influenced by HAART: 18%
probability of death versus 21% at 3 months, respectively, in
the pre-HAART and post-HAART period in France or 15%
deaths at 2 weeks and 31% at 10 weeks in four cohorts in
Thailand, Uganda, and South Africa [209, 210].
11. Antifungal Treatment
Several clinical trials or cohort studies regarding antifungal
therapy for AIDS-associated CM have been performed and
published over the last 22 years and are summarized in
Table 4 [74, 76, 85, 177–182, 185–197]. However, it is worth
noting thatmuch of these studies have been hampered by sev-
eral drawbacks such as low number of patients enrolled, low
dosages of antifungal employed, different end-points, short
follow-up. Current management of AIDS-associated CM is
largely based on the results of the landmark randomized trial
published over a decade ago [76]. It is based on three distinct
phases: induction, consolidation, and maintenance therapy.
The induction phase is aimed to achieve rapid fungicidal
activity to obtain CSF sterility using the combination of
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amphotericin B deoxycholate (0.7mg/kg/day) and 5- fluoro-
cytosine (100mg/kg/day) for two weeks. The combination of
amphotericin B deoxycholate (AmB) and fluorocytosine (5-
FC) is more rapidly fungicidal than amphotericin B alone
and is associated with a trend towards a higher proportion
of patients achieving a sterile CSF at 2 weeks and a reduced
relapse rate [76].The consolidation phase is the subsequent 8-
week treatment period with either fluconazole (400mg/day)
or itraconazole (400mg/day) as an alternative for patients
with fluconazole intolerance. The maintenance phase or
secondary prophylaxis of treatment for CM in HIV-infected
subjects is imperative in order to prevent the high relapse rate
of this meningitis. Oral fluconazole at a dosage of 200mg/day
has been shown to be superior to weekly intravenous AmB
[211], placebo [212], or oral itraconazole [213]. Although the
above mentioned treatment is endorsed by IDSA guidelines
as the recommended first line treatment of AIDS-associated
CM [123], it is far from being completely satisfactory because
during the induction phase, it is unable to achieve CSF
sterility in all patients and it is associated with a still high
acute mortality; moreover, one of its component (i.e., 5-FC)
is not available in most developing countries where CM is
prevalent. One of the goals that needs to be achieved in the
treatment of CM, especially among immunocompromised
patients, is that of rapidly and efficiently reduce the huge
burden of yeast cells in the CSF. In this regard in an elegant
randomized study performed in Thailand, using for the first
time the rate of reduction in CSF colony forming units
from serial quantitativeCSF cultures, Brouwer and coworkers
demonstrated that the combination of AmB plus 5-FC had
the highest and most rapid fungicidal activity compared to
AmB alone, AmB plus fluconazole or all the three drugs
together [183]. Since AmB shows concentration-dependent
antifungal activity, the same group conducted a random-
ized controlled trial in 64 HIV-infected antiretroviral na¨ıve
patients to compare the standard of care with a higher drug
dosage (i.e., 1mg/kg/day) [185]. Although they showed that
the higher dosage had a significantly greater early fungicidal
activity compared to the standard dose (−0.56 log cfu/mL
versus −0.45 log cfu/mL,𝑃 = .02), mortality at 2 and 10 weeks
was not statistically different in the two arms [185].
However, analyzing combined data of early fungicidal
activity collected from different cohorts, Bicanic and cowork-
ers were able to show that the magnitude of this was
inversely associated with mortality at 2 and 10 weeks and in a
multivariate models (that included altered mental status and
fungal burden), it remained independently associated with
mortality [207]. As discussed by the Authors it is unknown
if this relationship is linear or if exists a threshold value above
which no further benefit of early fungicidal activity will be
observed.
In consideration of the fact that 5-FC is presently unavail-
able in several resource-limited areas where, on the contrary,
fluconazole might be obtained free of charge through the
Pfizer program or as a cheap generic drug, a phase II
randomized open label trial was conducted in Thailand and
USAcomparing three arms (AmBat 0.7mg/kg versusAmBat
the same dosage plus fluconazole 400mg or 800mg per day)
[188]. Using a composite efficacy end-point (CSF negative
Table 3: Clinical manifestations of paradoxical and ART-associated
cryptococcosis.
Clinical syndrome References
Paradoxical cryptococcal IRIS
Meningitis
[13, 130, 135, 136, 138–
140, 145, 149, 150, 154–
158]
Other CNS-IRIS manifestations
(i) Intracranial space-occupying lesion/s [136, 146, 159, 160]
(ii) Meningoradiculitis [163]
(iii) Hearing loss [161]
Lymphadenopathy [135, 136, 145, 147, 151,158, 164]
Cutaneous and/or soft-tissue lesions [130, 165, 176]
Pneumonia or pulmonary nodules [130, 136, 145]
ART-associated cryptococcal IRIS
Unmasking meningitis [129, 135]
Lymphadenopathy [166, 169]
Cutaneous and/or soft-tissue lesions [168, 170]
Pneumonia [167]
culture, stable neurological function, and survival) the arm
employing higher dosage of fluconazole showed the better
response (53.7 versus 28.3 versus 42.5) at 2 weeks [188]. The
2011 WHO guidelines for the management of cryptococcal
disease in HIV-infected subjects strongly recommend treat-
ment with amphotericin-based regimens [214] but in the
real life a strategy employing fluconazole monotherapy is
generally used. High-dose fluconazole (1200mg/day) plus 5-
FC with or without a short-course (7 days) of AmB has been
shown to significantly enhance early fungicidal activity and
more rapid fungal clearance form CSF although the studies
were not powered for clinical end-points [192, 197].
A very interesting decision analysis study based on the
results of cryptococcal trials in resource-limited areas and
expected life assumptions, provided some evidence that a
short-course (1-week) of AmB (1mg/kg/d) associated with
high-dose fluconazole (1200mg/d) for 2 weeks is the most
cost-effective induction treatment among the 6 regimens
evaluated [215].
The French CryptoA/D prospective observational study
performed on both HIV-positive or negative patients with
a first episode of CM showed that also in the “real life”
the best regimen for induction therapy is the combination
of AmB and 5-FC [20]. Treatment failure at week 2 was
documented in 26% of patients receiving AmB+5-FC in
contrast with 56% with any other treatments (𝑃 < 0.001).
Moreover, a 5-FC prescription shorter than 14 days was
one of the variables independently associated with treatment
failure at 3 months of follow-up confirming the results of the
study of van der Horst [20, 76]. Interestingly the Authors
documented that only 49% of French clinicians adhered
to the recommendations of the IDSA guidelines to use
the combination therapy for meningoencephalitis [20]. In
a multivariate analysis the use of AmB+5-FC rather than
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AmB was independently associated with a high CSF CrAg
titre whereas the prescription of AmB+5-FC rather than
fluconazole was independently associated with high CSF
CrAg titre and younger age. One might suppose that older
patients are treated with fluconazole because of the better
profile of tolerability but this choice exposes patients to a risk
of worst outcome as it has been clearly documented.
AlthoughAmB is still recommended as the drug of choice
for induction therapy of CM by authoritative guidelines
[123, 214], its use is frequently complicated by infusion-
related adverse effects and nephrotoxicity that can affect
mortality [216]. Results from small studies have indicated
that liposomal amphotericin B (L-AMB) may represent a
safer alternative to AmB with similar mycological success
rates [179, 181]. A multicenter double-blind randomized
comparative study performed in USA and Canada using
2 different dosages of L-AMB (3 and 6mg/kg/day) versus
conventional AmB (0.7mg/kg/day) found similar results for
primary efficacy end-point (negative CSF culture at week
2) and in the mortality rate in the 3 groups of patients
(13.9%, 9.5%, and 11.5%, respectively, in the 3 and 6mg
of L-AMB and in the conventional AmB) [189]. Patients
treated with L-AMB had a significantly lower incidence of
infusion-related reactions compared with those treated with
AmB (𝑃 < .001) and less nephrotoxicity with the lower
dosage of L-AMB (𝑃 = .004). Thus the results of this study
confirmed that the main advantage using L-AMB instead
of AmB in the treatment of AIDS-associated cryptococcosis
is a better tolerability without any significant improvement
in the outcome. Recently the expert committee panel of
the British HIV Association recommended the use of L-
AMB (4mg/kg/d) as preferred amphotericin B preparation
for the induction therapy of AIDS-associated CM [217].
On the basis of economic considerations, other UK experts
argued strongly against this endorsement [218]. Finally, two
new questions, that will be discussed in the next session,
emerged as the consequence of the implementation of very
efficacious antiretroviral therapy in the HIV setting: (1) the
appropriate time of starting ARV (antiretroviral) therapy
after the diagnosis of CM; (2) the time and threshold of
CD4+ lymphocytes at which maintenance therapy can be
safely discontinued.
12. When to Start ARV Therapy
and When Discontinue Antifungal
Maintenance Therapy
Among HIV-infected patients with advanced disease such
as those with a diagnosis of CM, there is general agreement
that ARV therapy should be started as soon as possible since
its deferral is associated with further HIV-related diseases
and increased mortality. However, the risk of severe and
potentially fatal IRIS associated with an unsterilized CSF
infection is an argument against an early or concomitant
(with antifungal therapy) ARV therapy. An open-label ran-
domized strategy study of early (within 2 weeks) versus
deferred (after acute therapy for opportunistic infection
was completed) ARV therapy among subjects with different
opportunistic infections demonstrated that the early strategy
was associated with fewer AIDS progression and death [219].
However this study was underpowered with to regard CM
and presented a low incidence than expected of IRIS (7%).
In sharp contrast with the results of the above mentioned
study, another open-label prospective study conducted in
Zimbabwe showed a 3-fold greater risk of mortality in the
early ARV group (within 72 hours after CM diagnosis) in
comparison with the delayed ARV group (after 10 weeks of
treatment with fluconazole) [220]. Worth noting the Cryp-
tococcal Optimal ART Timing (COAT) study conducted in
Uganda and South Africa under the US National Institute of
Health sponsorship was ended prematurely after an interim
analysis found a 1.7 times worse survival observed among
patients receiving early ARV treatment (http://www.niaid
.nih.gov/news/newsreleases/2012/Pages/COAT.aspx).
It has been supposed but not proved that the fungistatic
effect of fluconazole used in one study [220] as opposed
to the fungicidal action of AmB used in the other study
[219] could account for an increased risk of IRIS [221]. On
the ground of this uncertainty guidelines offer options to
start ARV therapy between 2 and 10 weeks after antifungal
therapy [123, 214, 222]. The conditional recommendation of
the WHO guidelines that indicates a different time option
of deferred ARV initiation according to the drug regimen
used in the induction and consolidation treatment seems
reasonable [214].
The question regarding when antifungal maintenance
therapy can be safely discontinued in patients responding to
ARV therapy and at what threshold of CD4+ lymphocytes it
should be done has been so far addressed in five case studies
[223–227], three observational cohorts [228–230], and in one
randomized controlled trial [231]. A total of 227 patients have
been evaluated following discontinuation of prophylaxis:
they had a median CD4+ cell count ranging from 167 to
297 cells/𝜇L, a median duration of HAART ranging from
6 to 42.5 months and a median follow-up ranging from 9
to 28.4 months after discontinuation [232]. The calculated
incidence of relapse was very low and varied from 0 to 1.53
per 100 PY thus providing the basis for the indication of
discontinue maintenance therapy after at least 12 months of
antifungal therapy with undetectable HIVRNA (>3 months)
and a sustained CD4+ cell count > 100 cells/𝜇L [123].
13. Prevention
In the pre-HAART era, a randomized clinical trial com-
paring fluconazole 200mg/day with clotrimazole troches for
prevention of fungal infections in AIDS patients demon-
strated a sevenfold reduction in the risk of cryptococcosis
[233]. Subsequently several other studies some of which
not designed for cryptococcal prevention demonstrated that
weekly administration of fluconazole at different dosages
(ranging from 100mg up to 400mg) was successful as
primary prophylaxis of CM in patients with advanced HIV
disease [234–236]. However, all these studies were performed
in the pre-HAART era and the policy of primary prophylaxis
for CMwas not recommended because of the lack of evidence
14 ISRN AIDS
of any survival benefit, the high cost associated and the risk
of development of fungal resistance.
In contrast with the above mentioned lack of survival
benefit a randomized double-blind placebo-controlled study
performed inThailand showed a reduction of overall mortal-
ity (HR4.3) in patients receivingweekly fluconazole (400mg)
compared to placebo although the study had a low statistical
power with wide confidence intervals for the mortality
benefit (0.9–19.8) [237]. A case-control study performed in
a metropolitan area of United States characterized by a high
prevalence of indigent population and with a low prevalence
of HAART use (12–23%) showed a protective role of azole use
in preventing invasive cryptococcal disease [238].
Modelling of data from a high endemic region for crypto-
coccosis in resource-limited settings suggested that screening
for cryptococcal antigenwith preemptive treatmentwasmore
cost-effective in patients with CD4+ lymphocytes between
51–100 cells/𝜇L with primary prophylaxis better when CD4+
are below 50 cells/𝜇L [239].
Finally, a large double-blind randomized placebo con-
trolled trial conducted in Africa provided evidence that
fluconazole (200mg) three times weekly was effective as
primary prophylaxis against cryptococcal disease both before
and during the early ARV therapy [240]. Moreover, although
fluconazole therapy did not influence the all-cause mortality,
it indeed reduced the mortality due to cryptococcosis. The
results of this study make scientific strength to one of the
possible strategy to be implemented in high-risk patients
living in high-risk setting to protect against development of
cryptococcal disease until immune reconstitution occurs.
14. Conclusions
Cryptococcal meningitis remains a major cause of morbid-
ity and mortality among HIV-positive patients especially
in resource-poor areas. ART is responsible of a dramatic
improvement of outcome but it is associated with the possible
onset of IRIS that is potentially fatal. In this regard, the
optimal timing of ART beginning after the diagnosis of
HIV-associated cryptococcalmeningitis is unclear. Screening
severe immunocompromised HIV-positive patients with the
new lateral flow assay to detect CrAg is highly cost effective.
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